天康生物2026年累计生猪出栏有望突破500万头 70余家机构参加收购羌都畜牧线上交流会

Core Viewpoint - TianKang Biological plans to acquire 51% of Qiangdu Livestock for 1.275 billion yuan, aiming for absolute control and flexible long-term development, with Qiangdu becoming a subsidiary post-acquisition [1] Group 1: Acquisition Details - The acquisition will bind the interests of the original controlling shareholder and includes a profit commitment of at least 837 million yuan over three years [1] - Qiangdu Livestock has a strong profitability record, with 1.36 million pigs expected to be sold in 2024 and over 1.5 million in 2025, maintaining profitability even during low price periods [1] Group 2: Future Projections - From 2026 to 2028, Qiangdu Livestock is projected to reach sales of 1.5 million, 1.58 million, and 1.61 million pigs respectively, with TianKang's total pig sales expected to exceed 3.2 million in 2025 [2] - Post-acquisition, TianKang's total pig sales could surpass 4 million, aiming for a target of 5 million, potentially moving from the 20th to the top 10 in national rankings [2] Group 3: Strategic Benefits - The acquisition aligns with national policies and enhances TianKang's competitive strength by integrating Qiangdu's established breeding base and technical team [3] - The merger will leverage TianKang's resources in feed research, animal vaccines, and breeding, while benefiting from Qiangdu's scale and reputation, facilitating a collaborative upgrade in operations [3] - The consolidation is expected to significantly boost TianKang's revenue and profit levels, supporting its strategic development in the pig farming industry [3]